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Abstract
HIV is the top and tuberculosis is the second leading cause of death from infectious disease worldwide, with an
estimated 8.7 million incident cases of tuberculosis and 2.5 million new HIV infections annually. The World Health
Organization estimates that HIV prevalence among children with tuberculosis, in countries with moderate to high
prevalence, ranges from 10 to 60%. The mechanisms promoting susceptibility of people with HIV to tuberculosis
disease are incompletely understood, being likely caused by multifactorial processes.
Paediatric tuberculosis and HIV have overlapping clinical manifestations, which could lead to missed or late
diagnosis. Although every effort should be made to obtain a microbiologically-confirmed diagnosis in children with
tuberculosis, in reality this may only be achieved in a minority, reflecting their paucibacillary nature and the
difficulties in obtain samples. Rapid polymerase chain reaction tests, such as Xpert MTB/RIF assay, are increasingly
used in children. The use of less or non invasive methods of sample collection, such as naso-pharyngeal aspirates
and stool samples for a polymerase chain reaction-based diagnostic test tests and mycobacterial cultures is
promising technique in HIV negative and HIV positive children. Anti-tuberculosis treatment should be started
immediately at diagnosis with a four drug regimen, irrespective of the disease severity. Moreover, tuberculosis
disease in an HIV infected child is considered to be a clinical indication for initiation of antiretroviral treatment. The
World Health Organization recommends starting antiretroviral treatment in children as soon as anti-tuberculosis
treatment is tolerated and within 2- 8 weeks after initiating it. The treatment of choice depends on the child’s age
and availability of age-appropriate formulations, and potential drug interactions and resistance. Treatment of multi-
drug resistant tuberculosis in HIV-infected children follows same principles as for HIV uninfected children. There are
conflicting results on effectiveness of isoniazid preventive therapy in reducing incidence of tuberculosis disease in
children with HIV.
Conclusion: Data on HIV/TB co-infection in children are still lacking. There are on-going large clinical trials on the
prevention and treatment of TB/HIV infection in children that hopefully will help to guide an evidence-based
clinical practice in both resource-rich and resource-limited settings.
Global epidemiology of HIV and TB
Worldwide, 2 billion people are estimated to be latently
infected with tuberculosis (TB) [1], whilst there are an
estimated 35.3 million people living with HIV, 70% of
whom live in sub-Saharan Africa (SSA) [2]. HIV is the
top and TB is the second leading cause of death from
infectious disease worldwide [1]. Annually there are an
estimated 8.7 million (range, 8.3-9.0 million) incident
cases of TB and 2.5 million new HIV infections [1,2]. Of
the 8.7 million incident cases of TB in 2011, 1.1 million
(13%) were among people living with HIV [2]. There are
well established epidemiological and biological synergies
between HIV and TB, influencing the distribution, pro-
gression and outcomes of both infections. The HIV epi-
demic is a key factor behind the resurgence in TB
incidence worldwide and HIV is the pre-eminent risk
factor for the development of TB. One in eight incident
cases of TB occur in HIV positive individuals, with a
quarter of all TB deaths in people with HIV, while
around a fifth of HIV related deaths occur in incident
TB cases [2,3]. Much of the burden of TB and HIV co-
disease is in Africa, where one-third of the approxi-
mately 2.3 million people who developed TB in 2010
were HIV positive [1], although other regions strongly
affected by TB and HIV dual epidemics are India and
Eastern Europe [4,5].
The HIV epidemic has also had an impact on the age
related prevalence of TB disease, with a lowering in the
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peak age groups affected, such that in high HIV preva-
lence areas, the peak TB incidence rates are now seen
among adults aged 20-45 years [6].
Children and HIV
The impact of the HIV pandemic on children has been
huge, and children account for around 10% of new glo-
bal HIV infections with an estimated 3.4 million chil-
dren aged less than 15 years living with HIV in 2010
[7]. The survival of children in antiretroviral treatment
(ART) era has dramatically improved in both resource-
rich and resource-limited settings [8-12]. Although cov-
erage with ART is improving, it is estimated that in low
and middle income countries only around 34% of chil-
dren aged <15 years needing ART are estimated to be
receiving treatment, compared with 68% in adults
[2,7,13].
Epidemiology of paediatric HIV/TB disease
There are scarce data on the incidence of TB among
HIV positive children and the prevalence of HIV among
children diagnosed with TB, and the information that is
available is difficult to interpret due to problems with
diagnosis, under-ascertainment and selection of study
populations (i.e. most are recruited from hospitals or
referral hospitals rather than the community). The
World Health Organization (WHO) estimates that HIV
prevalence among children with TB, in countries with
moderate to high prevalence, ranges from 10 to 60% [7],
with the prevalence varying depending on the back-
ground rates of HIV infection and estimates from sev-
eral studies are summarised in Table 1 [14-21].
Estimated rates of TB among children with HIV also
vary widely, partly depending on whether the study is
taking place in a TB endemic area or not and on highly
active anti-retroviral treatment (HAART) coverage in
that area, but also due to the problems of reaching a
definitive diagnosis of TB in children with HIV and
under-ascertainment. In one large paediatric HIV clinic
in London, UK, there was an average of two children
with HIV per year who presented with active TB over a
15 year period (18/328, 5.5% of HIV infected patients
were treated for active TB) [22] and in a US cohort of
nearly 1500 HIV infected children, TB disease was
found 3%, with an incidence of 0.61 per 100 child-years
[23]. In contrast, in high prevalence countries, the inci-
dence of TB disease in HIV positive children is much
higher. Thus, in a South African retrospective study,
incidence of TB disease was estimated to be 23 per 100
child-years among HIV positive children receiving HIV
care [24]. With increasing coverage with ART, the inci-
dence of TB has been decreasing, but remains substan-
tially higher in HIV positive children than in the general
paediatric population [25].
Impact of HIV on pathogenesis of TB
HIV alters the pathogenesis of TB, increasing the risks
of developing active TB in those with latent infection as
well as in those newly exposed to TB. In the HIV-unin-
fected population, only around 10% of people infected
with TB will develop TB disease [1]. However, in HIV
positive people, there is a 20-30 fold increased relative
risk of developing TB disease from latent state com-
pared with that in people without HIV [3], an increase
that outweighs those of other risk factors such as mal-
nutrition. The mechanisms promoting susceptibility of
people with HIV to TB disease are incompletely under-
stood. Risk of active TB increases with depletion of CD4
Table 1 Prevalence of HIV among children with TB [14-21]
Study setting Year Study population HIV prevalence Reference
Zambia 1994 Children with clinical TB diagnosis (n=120) 56% Luo et al Tuberc Lung Dis 1994 [14]
Johannesburg,
South Africa
2008 Cultured confirmed cases of TB in children
aged <14 years (n=1317)
52% in children with drug-
susceptible TB; 53% in the 13 with
MDR-TB
Fairlie et al BMC Inf Dis 2011[15]
Mumbai, India 2002 Children with disseminated TB (n=68) 16% Karande et al J Trop Pediatr 2002
[16]
Rio de Janeiro,
Brazil
1999-
2008
Children attending a reference hospital
(n=473)
17% (but only 56% tested for HIV) Matos et al J Pediatr 2012 [17]
Cape Town, South
Africa
1999-
2004
Children born in 1999 and diagnosed with
TB in public health facilities up to 2004
(n=1607)
37% (but only 16% had HIV test
results available)
Moyo et al Int J Tuberc Lung Dis
2010 [18]
Santo Domingo,
Dominican Republic
1996 Children aged 18-59 months with clinical TB
diagnosis (n=189)
5.8% Espinal et al J Acquir Immune Defic
Syndr Hum Retrovirol 1996 [19]
Durban, South
Africa
1998-
1999
Hospitalised children with culture-confirmed
TB aged <13 years (n=118)
48% Jeena et al Int J Tuberc Lung Dis
2002 [20]
Abidjan, Côte
d’Ivoire
1994-
1995
Children aged 0-9 years with newly
diagnosed TB (out- and in-patients) (n=161)
19% Mukadi et al AIDS 1997 [21]
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T-cells, but studies have also shown that HIV positive
individuals in high TB incidence regions have an
increased risk of developing active TB in the first year
after HIV seroconversion, i.e. with high CD4 T-cell
counts [26]. In addition, HIV positive individuals on
ART with high CD4 T-cell counts continue to have an
increased risk of developing TB compared with unin-
fected controls. This suggests that although the loss of
cell-mediated immunity with HIV disease progression is
likely to be an important factor with respect to the
increased risk of active TB associated with HIV, this is
likely to be caused by multifactorial processes.
Studies have demonstrated depletion of TB-specific
CD4 T cells in peripheral blood and in the lung at early
stages of HIV disease, suggesting that TB-specific
adaptive immunity may be especially susceptible to HIV-
associated immune damage [27]. The essential role of
CD4 T cells in generation of granulomas, and the deple-
tion of such cells with HIV disease progression, may
explain the increased risk of extra-pulmonary TB (EPTB)
in HIV-positive patients [28]. Furthermore, the failure of
the declining CD4 T cell population to regulate and
maintain granulomas is one of the mechanisms proposed
to be behind the increasing risk of re-activation disease
in latently infected individuals with HIV. Turning to
innate immunity, apoptosis (programmed cell death) of
an infected macrophage is an important host immune
response to TB infection. Recent work has suggested that
in the context of HIV infection, apoptosis of alveolar
macrophages is decreased, possibly due to raised IL-10
(an anti-inflammatory cytokine) in the lung [29], which
may be a mechanism behind the increased susceptibility
of those with HIV to TB. Genetic variants are also known
to influence TB development in HIV positive patients. A
recent case-control study in Brazil showed the novel
association between certain inflammasome gene poly-
morphisms (i.e. CARD8 genetic variants) and the devel-
opment of TB infection in HIV positive subjects [30].
Challenges of diagnosis of TB in children with HIV
WHO guidelines state that diagnosis of TB in an HIV
positive child should follow the same approach as for
HIV-uninfected children, with taking into account the
history of TB contact, clinical features suggestive of TB
(such as prolonged cough, poor weight gain or weight
loss), positive tuberculin skin test (TST) ≥5mm consid-
ered to be positive in HIV infected individuals, and sug-
gestive chest X-ray signs [31].
Paediatric TB and HIV have overlapping clinical mani-
festations, including fever, weight loss and lymphadeno-
pathy, which combined with persistent cough, could
lead to missed or late diagnosis, or alternatively a mis-
diagnosis of either infection or concomitant infections
with similar clinical features. TB generally has a more
severe clinical presentation in HIV positive individuals
than in those uninfected. The risk of EPTB or dissemi-
nated TB is increased in HIV positive adults, particularly
with low CD4 T cell counts [28]. In a US study of HIV
positive adults with EPTB, there was a significantly
increased risk of central nervous system, meningeal or
disseminated TB disease compared to lymph node dis-
ease in those with severe immunosuppression (CD4
<100 cells/mm3) [32]. In the limited paediatric literature,
studies have reported no significant differences in the
frequency of EPTB between HIV positive and negative
children [20,21,33]. However, others have suggested that
HIV infected children with more advanced HIV disease
are at higher risk of EPTB and combination of extrapul-
monary and pulmonary TB disease [34,35]. Overall, the
clinical presentation of TB in HIV infected children,
may depend on degree of immunocompromise, with
severe, disseminated forms more frequently found in
patients with advanced HIV infection; however this link
is less well reported than in adults.
The presence of HIV co-infection compounds the
well-recognised challenges of reaching a definitive diag-
nosis in children with suspected TB. Although every
effort should be made to obtain a microbiologically-con-
firmed TB diagnosis in children, in reality this may only
be achieved in a minority, reflecting the paucibacillary
nature of much childhood TB, the inability of young
children to expectorate sputum, the difficulties of
obtaining gastric aspirates and the low yield of such
samples. Sputum induction with hypertonic saline was
found to be safe and useful for microbiological confir-
mation of pulmonary TB in both HIV positive and HIV
negative children in a study in South Africa: overall,
24% of children had a positive smear or culture for
Mycobacterium tuberculosis and induced sputum (IS)
samples had a three-times greater yield than gastric
lavage (GA), with no difference in yield by HIV infection
status [36]. This was later evaluated in the community
setting with 16.9% of clinically diagnosed TB cases con-
firmed microbiologically [37], highlighting the usefulness
of this diagnostic tool in the outpatient settings. How-
ever the need for electrical supply and special technical
equipment, together with the high work load and infec-
tious hazard are substantial obstacles for widespread use
of this method. It is important to note that low rates of
microbiological confirmation in paediatric TB are in
part due to low rates of obtaining the samples from
children. For example, European Centre for Disease Pre-
vention and Control (ECDC) surveillance demonstrated
that only 42% of children with TB reported to ECDC
had mycobacterial cultures sent in 2000-2009, however
of those who had their cultures sent, 40% were culture
positive [38]. It is important to highlight that every
effort needs to be undertaken to collect samples from
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children with suspected TB for microbiological
confirmation.
Rapid polymerase chain reaction (PCR) tests, such as
Xpert MTB/RIF assay, are increasingly used in children
with TB and are recommended by WHO as the initial
diagnostic test in patients suspected of MDR-TB or
HIV/TB [39]. The test is an important advance in rapid
detection of TB disease and detection of drug resistance.
The few prospective studies evaluating it in children
have showed that it is much more sensitive than micro-
scopy, with sensitivity being reported from 75 to 90% on
sputum samples and nearly 70% on gastric aspirates,
with comparable performance in HIV positive and HIV
negative children [40,41]. Although the sensitivity of
Xpert MTB/RIF test is higher than microscopy, a sub-
stantial proportion of children with negative test had
positive MTB cultures. Hence Xpert MTB/RIF test can-
not be used to rule out TB, and MTB culture remains a
necessary diagnostic tool.
The use of less or non invasive methods of sample
collection, such as naso-pharyngeal aspirates (NPA) and
stool samples for a PCR-based diagnostic test tests and
MTB cultures is promising technique which was evalu-
ated in HIV negative and HIV positive children. Small
pilot studies in South Africa reported on Xpert MTB/
RIF assay on stool in childhood TB. The first study
assessed Xpert on decontaminated stool sediment. It
showed that stool Xpert was equally sensitive to the
assay on GA, detecting 75% of children with intra-thor-
acic culture confirmed TB [42]. In another pilot study,
stool Xpert, which was performed directly on stool
detected 47% culture-confirmed TB (80% in HIV-
infected children and 33% in HIV-uninfected children)
compared to 65% cases detected by Xpert on IS [43].
The study used small stool volumes, and the authors
concluded that the sensitivity may be increased by an
improved protocol. Another paediatric study from the
South Africa compared NPA with IS: the sensitivity of
two Xpert MTB/RIF tests were comparable (71% vs
65%, P = 0.444), however the culture yield from NPA
was significantly less than from IS (96.6% vs 70.1%, P <
0.001) [44]. Stool and NPA can be useful add on or
alternative specimens in the settings where is unavail-
able and in older children in whom GA are difficult to
obtain. Urine lipoarabinomannan has been recently
shown to be useful in diagnosing TB in severely immu-
nocompromised adults, detecting up to 61% of culture-
confirmed TB cases with CD4<50 cells/mm3 [45]. There
are no reported studies in children to date.
With respect to TST, there is a high rate of false
negative results in HIV positive children. In a study in
Cape Town, among nearly 300 paediatric TB cases,
those with HIV were significantly less likely to have a
positive TST than those HIV negative (36% versus 59%)
[18]. In a further study in South Africa among HIV-
infected children with culture-confirmed TB, only 56%
had a positive TST [35]. There is considerable discre-
pancy between current recommendations on use of
interferon-g release assays (IGRA) and TST in diagnosis
of TB infection and TB disease in children [46]. A sys-
temic review and meta-analysis on IGRA in childhood
tuberculosis showed improved specificity of IGRA com-
pared with TST and similar accuracy between IGRA
and TST in detection of TB infection or TB disease;
however the tests showed high level of discordant
results and had lower sensitivity for HIV positive chil-
dren [47]. In a recent South African study comparing
performance of the TST and IGRA in children recruited
from hospital outpatient settings, while the proportion
with a positive TST did not vary according to HIV
infection status, HIV positive children were significantly
less likely to have a positive IGRA than HIV negative
children after adjusting for degree of TB exposure; in
addition, HIV negative children had an increasing prob-
ability of a positive TST with increasing age compared
to HIV positive children, after adjusting for degree of
TB exposure, Bacillus Calmette–Guérin (BCG) vaccina-
tion, malnutrition and past TB [48]. The authors con-
cluded that caution is needed in interpreting IGRA
results in the context of HIV infection, given their find-
ings that the test performance compared with TST is
differentially affected by age and HIV infection. Some
studies demonstrated that enzyme-linked immunospot
assay is more sensitive than TST in detection of active
TB in HIV positive children however the sensitivity was
not sufficiently high to rule out active TB [49,50].
Although in adults with TB and HIV, particularly
those with severe immunodeficiency, there may be aty-
pical chest X-ray findings, the limited studies in children
have not identified key differences in the radiological
presentation of TB according to HIV status [20,51,52].
HIV positive children may frequently have other respira-
tory opportunistic infections such as Pneumocystis jiro-
vecii pneumonia, lymphoid interstitial pneumonitis or
other bacterial or viral pneumonias, which can further
complicate diagnosis of pulmonary TB, for example, due
to similar clinical or radiological manifestations. How-
ever, the presence of one such opportunistic infection
does not preclude concurrent infection with another,
and the challenge is to identify all respiratory infections
present and to treat appropriately.
In a case series of 18 children with HIV and active TB
in London, nearly half of the children had not yet been
diagnosed with HIV at the time they presented with TB
[22]. The new directions in diagnosis of paediatric TB
and novel TB diagnostic tests which are under develop-
ment have been recently reviewed by Whittaker and col-
leagues [53].
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Clinical management of HIV/TB in children
Prognosis
Many paediatric studies reported that children experien-
cing HIV/TB co-disease have more severe disease and
higher mortality than HIV negative children, reflecting
the dual impact of the two infections. In the pre-ART
era, very high mortality rates were reported for children
with TB and HIV: in a retrospective study of HIV-
infected children with culture confirmed TB in South
Africa, 21% of children died whilst on TB therapy and a
further 18% after TB treatment was competed, mostly
(in 82% cases) due to causes other than TB [35]. In a
cohort study in Ethiopia, children with HIV infection
were around six times more likely to die from TB than
those without HIV [52]. In a study in Côte d’Ivoire, the
mortality rate in HIV-infected children with TB was
23% versus 4% in HIV-uninfected children, a 3.6 times
increased risk; of note all deaths among the children
with HIV occurred in those with severe immune sup-
pression [21]. Not all paediatric studies showed higher
TB associated mortality in HIV co-infected children: in
a Zambian autopsy study of 180 HIV positive and 84
HIV negative children who died of respiratory disease,
26% of the HIV-negative and 18% of the HIV positive
group died with TB (no significant difference), half of
the HIV positive children had more than one respiratory
disease or infection identified [54].
ART has modified HIV/TB co-infection epidemic and
had a great impact on TB disease incidence, morbidity
and mortality. In a study in the Democratic Republic of
Congo, ART halved the hazard of developing TB in
HIV-infected children [55], with a TB incidence rate in
those receiving ART of 10.2 per 100 person-years versus
20.4 per 100 person-years in those not yet on ART;
after 12 months of ART TB incidence decreased to 5.3
per 100 person-years. A recent prospective cohort study
conducted in Kenya on 689 HIV-infected children aged
6 weeks to 14 years, showed that longer time on ART
and longer duration of being in care before ART were
associated with lower prevalence of TB at enrolment
(adjusted hazard ratio [aHR] 0.91, P = 0.003 and aHR
0.87, P= 0.001 respectively) and lower incidence of TB
during the study (aOR 0.91, P< 0.001 and aOR 0.92, P <
0.001 respectively) [56]. These findings are consistent
with those from a South African retrospective cohort
study that reported that among children receiving ART,
incidence of clinically diagnosed TB declined from 21.1
per 100 person-years during their pre-ART follow-up to
6.4 per 100 person-years after ART initiation [57]. A
recent retrospective study from Soweto, South Africa,
showed that scaling-up of the public-funded antiretro-
viral treatment program resulted in 70.6% reduction of
culture-confirmed TB in HIV infected children in 4-year
period from 2005 to 2009. However in 2009 the
incidence of culture confirmed TB, was still 42-fold
times higher in HIV positive compared to HIV negative
children (460.7/100,000 vs. 11.0/100,000). Over three
quarters of co-infected children were severely immuno-
compromised [58]. Over 40% decline of TB incidence
was also observed in HIV negative children which
maybe in part due to increased ART coverage in adults
and the associated decreased TB transmission.
Treatment
Anti-TB treatment should be started immediately at TB
diagnosis. In the most recent guidance, WHO recom-
mends that all HIV positive children are started on
four-drug TB treatment, irrespective of the TB disease
severity (isoniazid, rifampicin, pyrazinamide and etham-
butol) and that intermittent therapy should be avoided
[13,59].
TB disease in a HIV infected child is considered to be
a clinical indication for initiation of ART [59]. WHO
2013 recommends starting ART in children as soon as
TB treatment is tolerated and within 2- 8 weeks after
initiating it [59]. The early start of ART is especially
relevant for children with moderate-to-severe immuno-
compromise. The recommendations are extrapolated
from adult trials, which showed that mortality is
decreased in severely immunocompromised patients
with CD4 <50 cells/mm3 with early start of ART
[60-62]. A paediatric retrospective study from Johannes-
burg, South Africa, in children, most of whom were
severely immunocompromised, showed that delaying
ART for longer than 8 weeks was associated with
increased mortality and worse virologic outcome [63].
The data from adult studies suggest that delayed ART
in patients with no or mild immunocompromise was
not associated with worse outcomes [60-62]. Therefore
some clinicians consider delaying ART in children with
no evidence of immunocompromise until TB treatment
is well tolerated or even until the end of TB treatment
in order to avoid potential drug interactions and signifi-
cantly increased pill burden [22].
The choice of ART depends on the child’s age and
availability of age appropriate formulations, whether the
child is already receiving treatment, their previous ART
exposure, and potential drug interactions. Significant
drug interactions occur with rifampicin, which is a
potent CYP3A4 inducer, with a co-administration with
nevirapine and protease inhibitors which are metabo-
lised through cytochrome C450 enzymes. This may lead
to a marked decrease in plasma concentration of these
drugs; therefore in order to maintain therapeutic levels
dose adjustment may need to be done when starting
and stopping rifampicin. The regimen of choice in
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children aged over 3 years is efavirenz (EFV)-based
ART, as EFV has less significant drug interaction with
rifampicin and dose adjustment is not required. EFV
capsule sprinkles have been recently licensed in children
aged over 3 months based on results of a paediatric
population model [64]. However EFV capsules are not
widely available in high HIV and TB prevalence settings,
and further studies are required to assure the efficacy of
EFV-based combinations in HIV/TB co-infected young
children.
If lopinavir/ritonavir based ART is used, to overcome
drug interactions with rifampicin, it will be necessary to
increase ritonavir to 1:1 of lopinavir/ritonavir [65,66]. In
settings where therapeutic drug level monitoring is
available, dose adjustment of rifampicin and lopinavir or
other protease inhibitors can be made based on the
results. If available, rifabutin, a less potent CYP3A4
inducer, should be used instead of rifampicin to reduce
drug interactions. ART-naïve children under 3 years of
age can be started on nevirapine-based ART but without
lead-in dose and maximum recommended dose (200mg/
mm3 twice daily) [59]. Some clinicians choose to
increase the maintenance dose of nevirapine by 20-30%
in order to reach an optimal exposure [67].
An alternative regimen in children is triple nucleoside
reverse transcriptase inhibitors administered for the
duration of anti-TB treatment [59]. This regimen has
less virological efficacy but no significant drug interac-
tion with rifampicin. It has been shown in a recent pae-
diatric trial in Uganda and Zimbabwe to be
immunologically and clinically similar to non-nucleoside
reverse transcriptase inhibitors based ART and therefore
may be valuable in children with controlled HIV infec-
tion who develop TB [68]. Information on drug interac-
tions and advice on dose modification can be found at
www.hiv-druginteractions.org.
There remains some debate with respect to duration of
TB therapy in HIV-infected children. There is no evidence
that HIV-infected children should have longer duration of
treatment than HIV uninfected children if a good response
to treatment is achieved. Generally HIV infected children
without severe TB disease can receive standard duration
of anti-TB treatment for 6 months, and the duration of
anti-TB treatment can be extended in cases with subopti-
mal response to treatment [31]. However in the latter
cases, poor adherence, suboptimal drug levels secondary
to insufficient dosing or drug interactions, drug resistance
and immune reconstitution inflammatory response should
be considered and addressed appropriately.
Multi drug resistant (MDR)-TB
There are limited data on the extent of MDR-TB among
HIV positive children. In one study in the Western Cape
Province, South Africa, 5% of HIV-infected children aged
<14 years with culture confirmed TB had MDR-TB [35].
A cross sectional study in children with culture con-
firmed TB in a setting with high prevalence of HIV
(Johannesburg, South Africa) showed no difference in
HIV prevalence in TB compared to MDR-TB (52.1% vs.
53.9% respectively), suggesting there is no association
between HIV infection and MDR-TB [15]. MDR-TB can
be devastating in HIV infected individuals as demon-
strated by the very high mortality rates in HIV positive
adults in early institution-based outbreaks with MDR-TB
and extensively drug resistant (XDR)-TB [69]. Advances
in treatment of both HIV and drug resistant TB, com-
bined with comprehensive care, have facilitated very
good treatment outcomes in HIV infected children with
MDR-TB and even XDR TB [70,71]. A retrospective
study from Western Cape Province, South Africa, on
children with culture-confirmed MDR-TB, with HIV pre-
valence of 43%, overall treatment success was achieved in
82%; multivariable analysis showed no significant associa-
tion of HIV infection with poor treatment outcome (OR
1.46 [95% CI, 0.46–4.63]; P=0.52) [72].
Treatment of MDR-TB in HIV infected children fol-
lows the same principles as for HIV uninfected children
as well outlined in the recent guidelines [73-75]. Based
on extrapolations from adult studies, children with
MDR-TB are recommended to receive TB treatment for
18-24 months regardless of their HIV status [75]. How-
ever, good results have been demonstrated with shorter
and less intensive regimens in children with non-severe
forms of TB disease [76]. Children with HIV/TB co-
infection should be monitored closely for potential over-
lapping and added toxicities of ART and second line TB
drugs. Attention to nutrition and adherence support
with provision of directly observed therapy are extre-
mely important.
Immune reconstitution inflammatory syndrome (IRIS)
Following initiation of ART in HIV/TB co-infected
patients, IRIS may develop - presenting with either clini-
cal manifestation of previously undiagnosed TB or para-
doxical exacerbation of already diagnosed TB disease in
spite of already initiated anti-TB treatment [77]. It
usually occurs in severely immunocompromised patients
and presents within 3 months of starting ART. It is fre-
quently associated with a substantial fall of viral load
and increase in CD4 count. Non-inflammatory drugs in
mild cases or steroids in moderate-to-severe cases are
usually required in the addition to perseverance with TB
and HIV treatment. Most patients can be managed
without stopping ART.
Perinatal TB/HIV
African studies carried out in the pre-ART era demon-
strated that recent pregnancy was associated with
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increased risk of developing active TB in HIV positive
women, which is associated with increased risk of
maternal mortality [78]. Infants of mothers with active
TB are at high risk of acquiring TB infection (usually
postnatally) and developing active disease [79]. The
extrapulmonary forms of the disease, miliary and menin-
geal TB, are greater risk factors for congenital TB [80].
In one study, at least 15% of mothers with active TB in
pregnancy had transmitted infection to their infants by
age three weeks [81]. In an Indian study of HIV-infected
postnatal women not receiving isoniazid TB preventative
therapy (IPT), there was a high maternal active TB inci-
dence (5 cases/100 person-years), and infants of mothers
with incident TB had a 3-fold increased mortality rate
compared with other infants [82]. Transmission and
outcomes are affected by duration of therapy before
delivery. Four months or more of therapy is protective
to the foetus. However, noncompliance with therapy
carries an increased risk of transmission of the Myco-
bacterium tuberculosis to the infant [83]. Further
research to guide policies for TB screening and IPT in
pregnant women with HIV is needed.
Prevention
Isoniazid preventive therapy
There are controversial results on effectiveness of TB
preventive therapy in reducing incidence of TB disease in
children with HIV. Zar and colleagues in a South African
clinical trial including nearly 300 children showed that
IPT halved mortality (8% versus 16%) and reduced TB
incidence from 10% to 4%, reducing the chance of devel-
oping TB (confirmed or probable) by 72% [84]. However
a recently conducted large double-blind, randomized,
placebo-controlled trial of pre-exposure isoniazid pro-
phylaxis against tuberculosis on 548 HIV infected chil-
dren and 804 HIV uninfected children immunized with
BCG vaccine, showed no significant difference in the
combined incidence of tuberculosis infection, tuberculo-
sis disease, or death between the isoniazid group and the
placebo group irrespective of HIV status [85].
The differences in coverage of ART and lack of expo-
sure to TB disease are the likely explanations for the
contrasting results, which was further underlined by
Mark Cotton of Stellenbosch University who partici-
pated as an investigator in both trials [84-86].
Recently, results on the use of 3 months of rifapentine
and isoniazid once weekly for people living with HIV
showing higher treatment completion rates and better
tolerance than 9 months of isoniazid administered daily.
This regimen was as well tolerated in HIV-infected as in
HIV negative individuals. Although increased risk of
selection for rifampicin resistance was observed in the
rifapentine/isoniazid group, the numbers were too few
for conclusions to be drawn [87].
BCG and the HIV-infected Infant
While the risks of adverse events associated with BCG
vaccination in HIV negative infants are low (<0.04% for
local disease and 0.0002% for disseminated disease),
HIV positive infants have a markedly increased risk of
developing local (5.6%) and disseminated BCG disease
(dBCG) (0.2%) [87]. Recently the WHO assessed the risk
of dBCG disease in HIV-positive infants to be approach-
ing 1% [31]. Moreover HIV infection severely impairs
the BCG-specific T cell responses during the first year
of life, giving little protection against tuberculosis in
HIV-infected infants. Considering the significant risk of
dBCG disease, these data strongly support the WHO
recommendation of not giving BCG to children who are
known to be infected with HIV [31]. However, in set-
tings where limited resources are available, BCG vacci-
nation is given at birth to all infants regardless of HIV
exposure, considering the high endemicity of tuberculo-
sis in populations with high HIV prevalence. Close fol-
low up of infants known to be born to HIV-infected
mothers and who received BCG at birth is recom-
mended in order to provide early identification and
treatment of any BCG-related complication [31].
Conclusion
TB and HIV both represent major threats to public
health worldwide. Renewed global interest led to
advances in recognising TB/HIV co-infection and
understanding the mechanisms promoting susceptibility
of HIV-infected people in developing TB disease as part
of a multifactorial process [26-30]. Diagnosis of HIV/TB
co-infection in children is still challenging. Paediatric
TB and HIV have overlapping clinical manifestations,
which could lead to missed or late diagnosis. TB disease
in a child should alert the clinician to the possibility of
HIV infection, particularly in high HIV prevalence set-
tings, where HIV counselling and testing to the child
and family should be strongly recommended. Difficulties
in TB diagnosis in children are mostly related to their
paucibacillary nature. New tests based on PCR have
been developed, being applied in samples that require
less invasive procedures such as stool and NPA and
showing to be useful especially in settings in whom GA
are difficult to obtain. Larger studies are needed to
establish the sensitivity of these tests to rule out TB in
children [42-44]. Few data are available about IGRA and
TST in HIV positive children, showing high level of dis-
cordant results and lower sensitivity in these patients.
Further well-designed and comparative studies on use of
IGRA in immunocompromised children are required
[46-50].
Following WHO 2013 recommendations, anti-TB
treatment should be started immediately after diagnosis
whereas ART could be delayed to 2-8 weeks after or as
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soon as TB therapy is tolerated. The regimen of choice
should be carefully addressed considering age, drug
interactions, especially if rifampicin is used, or MDR-TB
cases [13,59].
There are controversial results on effectiveness of pre-
ventive therapy in reducing incidence of TB disease in
HIV children. The last CROI meeting in 2013 reported
that primary isoniazid prophylaxis seemed ineffective in
preventing TB infection in young HIV-perinatally
exposed infants (<12 months) in TB endemic regions
[86]; nevertheless treatment of latent TB with isoniazid
was effective in avoid developing TB disease in HIV
infected children over 24 months of age [86]. Thus the
questions remain regarding the protective effect of IPT
in low TB burden settings. Moreover, shorter regimens
have been studied in adults, i.e. 3 months rifapentine
and isoniazid once weekly, with promising preliminary
results on efficacy and compliance [87]. There are on-
going large clinical trials (i.e. the PREVENT TB study,
SHINE-trial) on the prevention and treatment of TB/
HIV infection in children that should provide new,
much needed data on paediatric TB/HIV infection and
help to guide evidence-based clinical practice in both
resource-rich and resource-limited settings.
List of abbreviation used
ART: anti-retroviral treatment; BCG: bacillus Calmette–
Guérin; dBCG: disseminated BCG disease; ECDC: Eur-
opean Centre for Disease Prevention and Control; EFV:
efavirenz; EPTB: extra-pulmonary TB; GA: gastric aspi-
rate; IGRA: interferon-g release assays; IPT: Isoniazide
preventing therapy; IRIS: Immune reconstitution inflam-
matory syndrome; IS: induced sputum; MDR: multi
drug resistant; NPA: naso-pharyngeal aspirate; PCR:
polymerase chain reaction; SSA: sub-Saharan Africa; TB:
tuberculosis; TST: tuberculin skin test; WHO: World
Health Organization; XDR: extensively drug resistant
Competing interests
The authors declare that they have no competing interests
Declarations
Funding for this supplement came from the Italian Health Ministry /Young
Research Project.
This article has been published as part of BMC Infectious Diseases Volume 14
Supplement 1, 2014: Highlights in Pediatric Tuberculosis. The full contents of
the supplement are available online at http://www.biomedcentral.com/
bmcinfectdis/supplements/14/S1
Authors’ details
1Department of Health Sciences, Meyer Children University Hospital,
University of Florence, Florence, Italy. 2Department of Paediatric Infectious
Diseases, St Mary’s Hospital, Imperial College NHS Trust, London, United
Kingdom. 3Centre of Paediatric Epidemiology and Biostatistics, University
College London Institute of Child Health, London, WC1N 1EH, United
Kingdom.
Published: 8 January 2014
References
1. World Health Organization: Global tuberculosis report 2012.[http://apps.
who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf].
2. Global report: UNAIDS report on the global AIDS epidemic 2013. [http://
www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/
2013/gr2013/UNAIDS_Global_Report_2013_en.pdf].
3. Time to act. Save a million lives by 2015. Prevent and treat tuberculosis
among people living with HIV. [http://www.stoptb.org/assets/documents/
resources/publications/acsm/TB_HIV_Brochure_Singles.pdf].
4. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN,
Ramanathan U, Venkatesan P, Prabhakar R, Datta M: Risk of development
of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 2000,
4:839-844.
5. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG,
Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O, EuroSIDA study
group: Tuberculosis among HIV-positive patients across Europe: changes
over time and risk factors. AIDS 2011, 25:1505-1513.
6. Marais BJ, Rabie H, Cotton MF: TB and HIV in children - advances in
prevention and management. Paediatr Respir Rev 2011, 12:39-45.
7. World Health Organization: Global HIV/AIDS response. Progress report
2011.[http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf].
8. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V,
Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM, Collaborative HIV
Paediatric Study (CHIPS), National Study of HIV in Pregnancy and Childhood
(NSHPC): Morbidity, mortality, and response to treatment by children in
the United Kingdom and Ireland with perinatally acquired HIV infection
during 1996-2006: planning for teenage and adult care. Clin Infect Dis
2007, 45:918-924.
9. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P:
Reduction in mortality with availability of antiretroviral therapy for
children with perinatal HIV-1 infection. Italian Register for HIV Infection in
Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
10. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB,
Seage GR 3rd, Pediatric AIDS Clinical Trials Group 219/219C Study Team:
Long-term effectiveness of highly active antiretroviral therapy on the
survival of children and adolescents with HIV infection: a 10-year follow-
up study. Clin Infect Dis 2008, 46:507-515.
11. KIDS-ART-LINC Collaboration: Low risk of death, but substantial program
attrition in pediatric HIV treatment cohorts in Sub-Saharan Africa. J
Acquir Immune Defic Syndr 2008, 49:523-531.
12. Lumbiganon P, Kariminia A, Aurpibul L, Hansudewechakul R, Puthanakit T,
Kurniati N, Kumarasamy N, Chokephaibulkit K, Nik Yusoff NK, Vonthanak S,
Moy FS, Razali KA, Nallusamy R, Sohn AH, TREAT Asia Pediatric HIV
Observational Database (TApHOD): Survival of HIV-infected children: a
cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr
2011, 56:365-371.
13. Global update on HIV treatment 2013: results, impacts and
opportunities. [http://apps.who.int/iris/bitstream/10665/85326/1/
9789241505734_eng.pdf].
14. Luo C, Chintu C, Bhat G, Raviglione M, Diwan V, DuPont HL, Zumla A:
Human immunodeficiency virus type-1 infection in Zambian children
with tuberculosis: changing seroprevalence and evaluation of a
thioacetazone-free regimen. Tuber Lung Dis 1994, 75:110-115.
15. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA: High prevalence of
childhood multi-drug resistant tuberculosis in Johannesburg, South
Africa: a cross sectional study. BMC Infect Dis 2011, 11:28.
16. Karande S, Bhalke S, Kelkar A, Ahuja S, Kulkarni M, Mathur M: Utility of
clinically-directed selective screening to diagnose HIV infection in
hospitalized children in Bombay, India. J Trop Pediatr 2002, 48:149-155.
17. Matos TP, Kritski AL, Ruffino Netto A: Epidemiological aspects of
tuberculosis in children and adolescents in Rio de Janeiro. J Pediatr (Rio
J) 2012, 88:335-340.
18. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M,
Tameris M, Geldenhuys H, Hanekom W, Hussey G: Age-related tuberculosis
incidence and severity in children under 5 years of age in Cape Town,
South Africa. Int J Tuberc Lung Dis 2010, 14:149-154.
19. Espinal MA, Reingold AL, Pérez G, Camilo E, Soto S, Cruz E, Matos N,
Gonzalez G: Human immunodeficiency virus infection in children with
tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical
findings, and response to antituberculosis treatment. J Acquir Immune
Defic Syndr Hum Retrovirol 1996, 13:155-159.
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5
http://www.biomedcentral.com/1471-2334/14/S1/S5
Page 8 of 10
20. Jeena PM, Pillay P, Pillay T, Coovadia HM: Impact of HIV-1 co-infection on
presentation and hospital-related mortality in children with culture
proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung
Dis 2002, 6:672-678.
21. Mukadi YD, Wiktor SZ, Coulibaly IM, Coulibaly D, Mbengue A, Folquet AM,
Ackah A, Sassan-Morokro M, Bonnard D, Maurice C, Nolan C, Kreiss JK,
Greenberg AE: Impact of HIV infection on the development, clinical
presentation, and outcome of tuberculosis among children in Abidjan,
Côte d’Ivoire. AIDS 1997, 11:1151-1158.
22. Cohen JM, Whittaker E, Walters S, Lyall H, Tudor-Williams G, Kampmann B:
Presentation, diagnosis and management of tuberculosis in HIV-infected
children in the UK. HIV Med 2008, 9:277-284.
23. Thomas P, Bornschlegel K, Singh TP, Abrams EJ, Cervia J, Fikrig S,
Lambert G, Mendez H, Kaye K, Bertolli J: Tuberculosis in human
immunodeficiency virus-infected and human immunodeficiency virus-
exposed children in New York City. The New York City Pediatric
Spectrum of HIV Disease Consortium. Pediatr Infect Dis J 2000, 19:700-706.
24. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ: Clinical
presentation and outcome of tuberculosis in human immunodeficiency
virus infected children on anti-retroviral therapy. BMC Pediatr 2008, 8:1.
25. Jensen J, Álvaro-Meca A, Micheloud D, Díaz A, Resino S: Reduction in
mycobacterial disease among HIV-infected children in the highly active
antiretroviral therapy era (1997-2008). Pediatr Infect Dis J 2012, 31:278-283.
26. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S:
How soon after infection with HIV does the risk of tuberculosis start to
increase? A retrospective cohort study in South African gold miners. J
Infect Dis 2005, 191:150-158.
27. Geldmacher C, Zumla A, Hoelscher M: Interaction between HIV and
Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the
development of active tuberculosis. Curr Opin HIV AIDS 2012, 7:268-275.
28. Naing C, Mak JW, Maung M, Wong SF, Kassim AI: Meta-analysis: the
association between HIV infection and extrapulmonary tuberculosis.
Lung 2013, 191:27-34.
29. Patel NR, Swan K, Li X, Tachado SD, Koziel H: Impaired M. tuberculosis-
mediated apoptosis in alveolar macrophages from HIV+ persons:
potential role of IL-10 and BCL-3. J Leukoc Biol 2009, 86:53-60.
30. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJ,
Crovella S: Susceptibility to Mycobacterium tuberculosis infection in HIV-
positive patients is associated with CARD8 genetic variant. J Acquir
Immune Defic Syndr 2013, 63:147-151.
31. WHO, UATLD: Guidance for national tuberculosis and HIV programmes
on the management of tuberculosis in HIV-infected children:
Recommendations for a public health approach.[http://www.theunion.
org/index.php/en/resources/technical-publications/item/759-guidance-for-
national-tuberculosis-and-hiv-programmes-on-the-management-of-
tuberculosis-in-hiv-infected-children-recommendations-for-a-public-health-
approach].
32. Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK,
Kraft CS: Site of extrapulmonary tuberculosis is associated with HIV
infection. Clin Infect Dis 2012, 55:75-81.
33. Soeters M, de Vries AM, Kimpen JL, Donald PR, Schaaf HS: Clinical features
and outcome in children admitted to a TB hospital in the Western
Cape–the influence of HIV infection and drug resistance. S Afr Med J
2005, 95:602-606.
34. Chan SP, Birnbaum J, Rao M, Steiner P: Clinical manifestation and
outcome of tuberculosis in children with acquired immunodeficiency
syndrome. Pediatr Infect Dis J 1996, 15:443-447.
35. Hesseling AC, Westra AE, Werschkull H, Donald PR, Beyers N, Hussey GD, El-
Sadr W, Schaaf HS: Outcome of HIV infected children with culture
confirmed tuberculosis. Arch Dis Child 2005, 90:1171-1174.
36. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G: Induced sputum versus
gastric lavage for microbiological confirmation of pulmonary
tuberculosis in infants and young children: a prospective study. Lancet
2005, 365:130-134.
37. Moore HA, Apolles P, de Villiers PJ, Zar HJ: Sputum induction for
microbiological diagnosis of childhood pulmonary tuberculosis in a
community setting. Int J Tuberc Lung Dis 2011, 15:1185-1190.
38. European Centre for Disease Prevention and Control: World Tuberculosis
Day 2011. Three key messages on childhood tuberculosis. Key message
3. Stockholm. 2011 [http://ecdc.europa.eu/en/publications/Publications/
1103_TB_SUR_2009.pdf].
39. WHO Information note 2013. Xpert MTB/RIF increases timely TB
detection among people living with HIV and saves lives. [http://www.
who.int/tb/challenges/hiv/Xpert_TBHIV_Information_Note_final.pdf].
40. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, Boehme CC,
Zemanay W, Zar HJ: Accuracy of the Xpert MTB/RIF test for the diagnosis
of pulmonary tuberculosis in children admitted to hospital in Cape
Town, South Africa: a descriptive study. Lancet Infect Dis 2011, 11:819-824.
41. Bates M, O’Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R,
Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N,
Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A: Assessment of the
Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage
aspirates in children in sub-Saharan Africa: a prospective descriptive
study. Lancet Infect Dis 2013, 13:36-42.
42. Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP: Rapid
diagnosis of pediatric intrathoracic tuberculosis from stool samples
using the Xpert MTB/RIF Assay: a pilot study. Pediatr Infect Dis J 2012,
31:1316.
43. Nicol MP, Spiers K, Workman L, Isaacs W, Munro J, Black F, Zemanay W,
Zar HJ: Xpert MTB/RIF testing of stool samples for the diagnosis of
pulmonary tuberculosis in children. Clin Infect Dis 2013, 57:18-21.
44. Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC,
Zemanay W, Nicol MP: Rapid molecular diagnosis of pulmonary
tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis
2012, 55:1088-1095.
45. Lawn SD, Kerkhoff AD, Vogt M, Wood R: Diagnostic accuracy of a low-
cost, urine antigen, point-of-care screening assay for HIV-associated
pulmonary tuberculosis before antiretroviral therapy: a descriptive study.
Lancet Infect Dis 2012, 12:201-209.
46. Denkinger CM, Dheda K, Pai M: Guidelines on interferon-γ release assays
for tuberculosis infection: concordance, discordance or confusion? Clin
Microbiol Infect 2011, 17:806-814.
47. Mandalakas AM, Detjen AK, Hesseling AC: Can we accurately diagnose
tuberculosis infection in children? Pediatr Infect Dis J 2011, 30:817-818.
48. Mandalakas AM, van Wyk S, Kirchner HL, Walzl G, Cotton M, Rabie H, Kriel B,
Gie RP, Schaaf HS, Hesseling AC: Detecting tuberculosis infection in HIV-
infected children: a study of diagnostic accuracy, confounding and
interaction. Pediatr Infect Dis J 2013, 32:111-118.
49. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A: Diagnosis
of tuberculosis in South African children with a T-cell-based assay: a
prospective cohort study. Lancet 2004, 364:2196-2203.
50. Davies MA, Connell T, Johannisen C, Wood K, Pienaar S, Wilkinson KA,
Wilkinson RJ, Zar HJ, Eley B, Beatty D, Curtis N, Nicol MP: Detection of
tuberculosis in HIV-infected children using an enzyme-linked
immunospot assay. AIDS 2009, 23:961-969.
51. Ramírez-Cardich ME, Kawai V, Oberhelman RA, Bautista CT, Castillo ME,
Gilman RH: Clinical correlates of tuberculosis co-infection in HIV-infected
children hospitalized in Peru. Int J Infect Dis 2006, 10:278-281.
52. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J: Impact of human
immunodeficiency virus 1 infection on clinical presentation, treatment
outcome and survival in a cohort of Ethiopian children with
tuberculosis. Pediatr Infect Dis J 2002, 21:1053-1061.
53. Whittaker E, Zar HJ: Promising directions in the diagnosis of childhood
tuberculosis. Expert Rev Respir Med 2012, 6:385-395.
54. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F,
Mwaba P, Bhat G, Terunuma H, Zumla A, UNZA-UCLMS Project Paediatric
Post-mortem Study Group: Lung diseases at necropsy in African children
dying from respiratory illnesses: a descriptive necropsy study. Lancet
2002, 360:985-990.
55. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F: Anti-
retroviral therapy reduces incident tuberculosis in HIV-infected children.
Int J Epidemiol 2009, 38:1612-1621.
56. Abuogi LL, Mwachari C, Leslie HH, Shade SB, Otieno J, Yienya N, Sanguli L,
Amukoye E, Cohen CR: Impact of expanded antiretroviral use on
incidence and prevalence of tuberculosis in children with HIV in Kenya.
Int J Tuberc Lung Dis 2013, 17:1291-1297.
57. Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M,
Violari A, Gray GE, Chaisson RE, McIntyre JA, Meyers T: HAART and risk of
tuberculosis in HIV-infected South African children: a multi-site
retrospective cohort. Int J Tuberc Lung Dis 2009, 13:862-867.
58. Dangor Z, Izu A, Hillier K, Solomon F, Beylis N, Moore DP, Nunes MC,
Madhi SA: Impact of the Antiretroviral Treatment Program on the
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5
http://www.biomedcentral.com/1471-2334/14/S1/S5
Page 9 of 10
Burden of Hospitalization for Culture-confirmed Tuberculosis in South
African Children: A Time-series Analysis. Pediatr Infect Dis J 2013,
32:972-977.
59. World Health Organisation: Consolidated guidelines on the use of
antiretroviral drugs for treating and preventing HIV infection:
recommendations for a public health approach. 2013 [http://apps.who.
int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf].
60. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL,
Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G,
Abdool Karim Q: Integration of antiretroviral therapy with tuberculosis
treatment. N Engl J Med 2011, 365:1492-1501.
61. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y,
Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S,
Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE,
CAMELIA (ANRS 1295–CIPRA KH001) Study Team: Earlier versus later start
of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J
Med 2011, 365:1471-1481.
62. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS,
Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U,
Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S,
Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A,
Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group
Study A5221: Timing of antiretroviral therapy for HIV-1 infection and
tuberculosis. N Engl J Med 2011, 365:1482-1491.
63. Yotebieng M, Van Rie A, Moultrie H, Cole SR, Adimora A, Behets F,
Meyers T: Effect on mortality and virological response of delaying
antiretroviral therapy initiation in children receiving tuberculosis
treatment. AIDS 2010, 24:1341-1349.
64. Food and Drug Administration (U.S.): Sustiva (efavirenz) pediatric patients
labeling update. 2013 [http://www.fda.gov/ForConsumers/ByAudience/
ForPatientAdvocates/HIVandAIDSActivities/ucm350744.htm].
65. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G,
McIlleron HM: Effect of rifampicin on lopinavir pharmacokinetics in HIV-
infected children with tuberculosis. J Acquir Immune Defic Syndr 2008,
47:566-569.
66. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T:
Antiretroviral therapy outcomes in HIV-infected children after adjusting
protease inhibitor dosing during tuberculosis treatment. PLoS One 2011,
6:17273.
67. Shah I, Swaminathan S, Ramachandran G, Kumar AK, Goray A, Chaddha U,
Tayal S, Lala M: Serum Nevirapine and Efavirenz concentrations and
effect of concomitant rifampicin in HIV infected children on
antiretroviral therapy. Indian Pediatr 2011, 48:943-947.
68. ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-
Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M,
Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C,
Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM:
Routine versus clinically driven laboratory monitoring and first-line
antiretroviral therapy strategies in African children with HIV (ARROW): a
5-year open-label randomised factorial trial. Lancet 2013, 381:1391-1403.
69. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G, Tugela Ferry Care and
Research (TF CARES) Collaboration: Multidrug-resistant and extensively
drug-resistant tuberculosis: implications for the HIV epidemic and
antiretroviral therapy rollout in South Africa. J Infect Dis 2007, 196(Suppl
3):482-490.
70. Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC,
Mukherjee JS, Seung KJ: Outcomes of comprehensive care for children
empirically treated for multidrug-resistant tuberculosis in a setting of
high HIV prevalence. PLoS One 2012, 7:37114.
71. Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR,
Friedland G, Shah NS: Extensively drug-resistant tuberculosis in children
with human immunodeficiency virus in rural South Africa. Int J Tuberc
Lung Dis 2010, 14:1244-1251.
72. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS: Culture-
confirmed multidrug-resistant tuberculosis in children: clinical features,
treatment, and outcome. Clin Infect Dis 2012, 54:157-166.
73. Schaaf HS, Marais BJ: Management of multidrug-resistant tuberculosis in
children: a survival guide for paediatricians. Paediatr Respir Rev 2011,
12:31-38.
74. Poorana Ganga Devi NP, Swaminathan S: Drug-resistant tuberculosis:
pediatric guidelines. Curr Infect Dis Rep 2013, 15:356-363.
75. USAID: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis.
Management of drug-resistant tuberculosis in children: a field guide.
2012 [http://sentinelproject.files.wordpress.com/2012/11/
sentinel_project_field_guide_2012.pdf].
76. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS: High treatment
success in children treated for multidrug-resistant tuberculosis: an
observational cohort study. Thorax 2013, Epub ahead of print.
77. Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M,
Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX,
CAMELIA (ANRS 1295 – CIPRA KH001) Study Team: Paradoxical
tuberculosis-associated immune reconstitution inflammatory syndrome
after early initiation of antiretroviral therapy in a randomized clinical
trial. AIDS 2013, 27:2577-2586.
78. Leroy V, Msellati P, Lepage P, Batungwanayo J, Hitimana DG, Taelman H,
Bogaerts J, Boineau F, Van de Perre P, Simonon A: Four years of natural
history of HIV-1 infection in african women: a prospective cohort study
in Kigali (Rwanda), 1988-1993. J Acquir Immune Defic Syndr Hum Retrovirol
1995, 9:415-421.
79. Donald PR, Marais BJ, Barry CE 3rd: Age and the epidemiology and
pathogenesis of tuberculosis. Lancet 2010, 375:1852-1854.
80. Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke Y, Källenius G,
Lindquist L: Evaluation of outpatients with suspected pulmonary
tuberculosis in a high HIV prevalence setting in Ethiopia: clinical,
diagnostic and epidemiological characteristics. Scand J Infect Dis 2002,
34:331-337.
81. Pillay T, Sturm AW, Khan M, Adhikari M, Moodley J, Connolly C, Moodley D,
Padayatchi N, Ramjee A, Coovadia HM, Sullivan JL: Vertical transmission of
Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-
infection. Int J Tuberc Lung Dis 2004, 8:59-69.
82. Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi S,
Khandekar M, Karmarkar A, Kulkarni V, Sastry J, Mave V, Suryavanshi N,
Thakar M, Kulkarni S, Tripathy S, Sambarey P, Patil S, Paranjape R,
Bollinger RC, Jamkar A, Six Week Extended-Dose Nevirapine (SWEN) India
Study Team: Maternal tuberculosis: a risk factor for mother-to-child
transmission of human immunodeficiency virus. J Infect Dis 2011,
203:358-363.
83. Adhikari M, Jeena P, Bobat R, Archary M, Naidoo K, Coutsoudis A, Singh R,
Nair N: HIV-Associated Tuberculosis in the Newborn and Young Infant.
Int J Pediatr 2011, 2011:354208.
84. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H,
Lombard CJ: Effect of isoniazid prophylaxis on mortality and incidence of
tuberculosis in children with HIV: randomised controlled trial. BMJ 2007,
334:136.
85. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P,
McSherry G, Mitchell C, P1041 Study Team: Primary isoniazid prophylaxis
against tuberculosis in HIV-exposed children. N Engl J Med 2011,
365:21-31.
86. Report of the HIV/TB Research meeting held in conjunction with the
20th Conference on Retroviruses and Opportunistic Infections (CROI
2013). [http://www.who.int/tb/challenges/hiv/tbhiv_at_croi_2013_report.
pdf].
87. The PREVENT TB Study. Rifapentine + isoniazid to prevent TB among
people living with HIV: interim data and pending issues. [http://www.
who.int/tb/challenges/hiv/
sterling_prevent_tb_study_26_hiv_croi_03mar2013.pdf].
doi:10.1186/1471-2334-14-S1-S5
Cite this article as: Venturini et al.: Tuberculosis and HIV co-infection in
children. BMC Infectious Diseases 2014 14(Suppl 1):S5.
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5
http://www.biomedcentral.com/1471-2334/14/S1/S5
Page 10 of 10
